Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

Background Bladder cancer is an important public health concern due to its prevalence, high risk of recurrence and associated cost of management. Although BCG instillation for urothelial cancer treatment is the gold-standard treatment for this indication, repeated BCG treatments are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Sylvain, Chevalier, Mathieu F, Benmerzoug, Sulayman, Cesson, Valérie, Schneider, Anna K, Rodrigues-Dias, Sonia-Cristina, Dartiguenave, Florence, Lucca, Ilaria, Jichlinski, Patrice, Roth, Beat, Nardelli-Haefliger, Denise, Derré, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413168/
https://www.ncbi.nlm.nih.gov/pubmed/36002184
http://dx.doi.org/10.1136/jitc-2022-004880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413168/
https://www.ncbi.nlm.nih.gov/pubmed/36002184
http://dx.doi.org/10.1136/jitc-2022-004880

Ejemplares similares